AMD Since Anti-VEGF

A National Eye Institute (NEI) study* confirms that anti-VEGF treatments have greatly improved the prognosis for patients with the wet form of age-related macular degeneration (wAMD) during the past decade. In the study of nearly 650 people, half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with [Read More]

Eye Drops for Wet AMD Enter Phase 3 Trials

Ohr Pharmaceutical has announced that the first patient has been enrolled in a Phase III clinical trial of the company’s lead drug candidate “Squalamine”, also known as OHR-102, for the treatment of neovascular age-related macular degeneration (wet AMD). “The Phase III clinical program will examine the potential of Squalamine, when administered as part of a combination therapy, [Read More]

Smoking and AMD—Are E-Cigarettes the Answer?

by Dan Roberts You’ve heard it before: “Tobacco Smoking Is A Major Cause Of Age Related Macular Degeneration”. According to most research, individuals 65 years of age and over double their risk of developing age-related macular degeneration (AMD) if they smoke. Why? Because tobacco smoking: Reduces levels of plasma antioxidant, a substance in the blood [Read More]

Sleeping Too Much Will *Not* Cause Blindness

Editorial by Dan Roberts Recent research has found an association between longer sleep duration and advanced dry age-related macular degeneration (dAMD), also known as geographic atrophy. This has been misconstrued by at least one media outlet to mean that too much sleep might actually cause the disease. That is absolutely untrue. According to the researchers, “Sleeping [Read More]